74
experience [ 29 ]. Until then, individualized application of treatment guidelines
through shared decision-making with patients will be pursued. Such decision-
making should recognize the tradeoff between optimal BP, side effects, cardiovas-
cular risk reduction, and quality of life.
References
- Judd E, Calhoun DA. Management of hypertension in CKD: beyond the guidelines. Adv
Chronic Kidney Dis. 2015;22:116–22. - Bangash F, Agarwal R. Masked hypertension and white-coat hypertension in chronic kidney
disease: a meta-analysis. Clin J Am Soc Nephrol. 2009;4:656–64. - Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M, et al. Disparate estimates of
hypertension control from ambulatory and clinic blood pressure measurements in hypertensive
kidney disease. Hypertension. 2009;53:20–7. - Modolo R, de Faria AP, Almeida A, Moreno H. Resistant or refractory hypertension: are they
different? Curr Hypertens Rep. 2014;16:485. - Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension:
diagnosis, evaluation, and treatment. A scientific statement from the American Heart
Association Professional Education Committee of the Council for High Blood Pressure
Research. Hypertension. 2008;51:1403–19. - Boswell L, Pascual J, Oliveras A. Resistant hypertension: do all definitions describe the same
patients? J Hum Hypertens. 2015;29:530–4. - James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014
evidence-based guideline for the management of high blood pressure in adults: report from the
panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;
311:507–20. - Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical
practice guidelines for the management of hypertension in the community a statement by the
American Society of Hypertension and the International Society of Hypertension. J Hypertens.
2014;32:3–15. - Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutiérrez OM, Irvin MR, et al. Prevalence of
apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc
Nephrol. 2013;8:1583–90. - Gijón-Conde T, Graciani A, Banegas JR. Resistant hypertension: demography and clinical
characteristics in 6292 patients in a primary health care setting. Rev Esp Cardiol. 2014;67:
270–6. - Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S, et al. Prevalence and prog-
nostic significance of apparent treatment resistant hypertension in chronic kidney disease:
report from the chronic renal insufficiency cohort study. Hypertension. 2016;67:387–96. - Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence
and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:
1635–42. - Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al.
Cardiovascular outcome in treated hypertensive patients with responder, masked, false resis-
tant, and true resistant hypertension. Am J Hypertens. 2005;18:1422–8. - Salles GF, Cardoso CL, Muxfeldt ES. PRognostic influence of office and ambulatory blood
pressures in resistant hypertension. Arch Intern Med. 2008;168:2340–6. - De Nicola L, Borrelli S, Gabbai FB, Chiodini P, Zamboli P, Iodice C, et al. Burden of resistant
hypertension in hypertensive patients with non-dialysis chronic kidney disease. Kidney Blood
Press Res. 2011;34:58–67.
A. Odudu et al.